Cureline Lead Generation Strategy

Overview

This article documents the proposed lead generation strategy developed for ^[1] following a complimentary strategy session with Jack Wilson (Business Development) and Mark Hope (Asymmetric Applications Group) in December 2025. Two proposals are pending CEO review for Q1 2026 planning: a full omnichannel lead-gen campaign and a standalone SEO/website optimization engagement.

Cureline competes against significantly larger rivals — iSpecimen, BioIVT, Discovery Life Sciences — and the proposed strategy is built around an asymmetric positioning framework: leveraging unique assets rather than attempting to match competitors on scale or spend.

Situation Analysis

Website & SEO Baseline

Cureline's website is the primary liability identified in pre-call research:

Key problems:
- Ranks for zero commercial or transactional keywords — invisible to active buyers
- 87% of traffic landing on the homepage signals poor internal linking and no service-page visibility
- Website is not conversion-optimized; no clear path for a prospect to become a lead
- Website is managed by an external outsourced vendor (contact: Harminder), creating delays for any updates

Internal Constraints

• Small commercial team of 3; only Jack Wilson is commercially focused (the other two are an MD and a PhD scientist)
• Recent merger with a Delaware company has created decision-making uncertainty — CEO sign-off required before any engagement
• Previous cold email outreach vendor was terminated this quarter due to poor ROI
• No in-house developer or marketing capability

Asymmetric Positioning Framework

Rather than competing on budget or brand recognition, the strategy positions Cureline around six differentiators that larger, PE-backed competitors cannot credibly claim:

1. Woman-Owned Small Business — Satisfies diversity procurement requirements at many target accounts; a direct purchasing advantage in certain institutional and government-adjacent deals
2. NIH Consortium Founder — Third-party validation that money cannot buy; supports "Trusted by the NIH" messaging
3. Founder-Led — Signals stability and customer focus vs. PE-backed rivals (BioIVT, Discovery Life Sciences) subject to cost-cutting, acquisition risk, and quarterly earnings pressure
4. Boutique Scale — Enables custom protocols, direct access to scientific leadership, faster turnaround, and willingness to take on smaller projects that large players decline
5. Baltic Facility — First-mover advantage for European clients seeking regional sourcing or compliance flexibility
6. Oncology Specialization — Deep domain expertise vs. generalist competitors; a credibility signal for oncology-focused buyers

Framing: "You're never going to outscale Discovery Life or outspend BioIVT — but you don't have to. You take advantage of the things you have that they don't."

Proposed Solutions

Option 1: Full Omnichannel Lead-Gen Campaign

Goal: Double the number of inbound inquiries and double the conversion rate of prospects to customers (Jack Wilson's stated success criteria; a 50%+ improvement would be considered a win).

Approach:
1. Identify 3–4 priority service offerings to focus on (e.g., histopathology, oncology biospecimens)
2. Build a targeted prospect list of companies and contacts likely to need those services
3. Execute outreach across multiple channels simultaneously:
- Cold email outreach — sequenced, personalized campaigns to the prospect list
- Direct mail — physical outreach for higher-value or harder-to-reach targets
- Google Ads — paid search targeting commercial/transactional keywords for priority services
- SEO — organic search visibility for the same keyword targets
4. Develop sales enablement materials for in-person touchpoints (trade shows, conferences, client meetings): brochures, sell sheets, one-pagers
5. Implement attribution tracking to measure lead source and conversion at each stage

Team (monthly retainer model):
- Account Manager
- Strategist
- Designer
- Developer
- Content Specialist

This 5-person team effectively becomes Cureline's outsourced marketing organization.

Measurement: Establish baseline lead volume → set quarterly targets → reverse-engineer required prospect contacts and engagement rates → report against targets monthly.

Option 2: SEO & Website Optimization (Standalone)

Goal: Improve organic search visibility and convert existing and new traffic into qualified leads.

Scope:
- SEO: Keyword research focused on commercial and transactional intent; on-page optimization; internal linking restructure to drive traffic to service pages rather than the homepage
- Conversion Rate Optimization (CRO): Redesign key pages to include clear calls-to-action and lead capture mechanisms
- Website Rebuild (recommended): Full rebuild would give Cureline complete control over the site, eliminate dependency on the external vendor, and allow proper integration of underrepresented services (e.g., histopathology). Jack Wilson expressed strong personal interest in this option.

Rationale for rebuild: The current site is built on custom code managed by an outsourced vendor, making iterative improvements slow and costly. A rebuild on a manageable CMS would enable the internal team to make updates independently and allow SEO and CRO work to be implemented without third-party delays.

Next Steps & Status

Related

• ^[2]
• ^[3]
• ^[4]
• ^[5]